Dr. Liang Cheng published the article “Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine” in the October 2026  issue of European Urology (Journal impact factor 29).

Hereditary renal cancers account for an estimated 3–5% of all renal cell carcinomas (RCCs), yet many affected patients remain undiagnosed and never undergo germline genetic testing. This article highlights the importance of recognizing hereditary disease and emphasizes a shift toward individualized care guided by tumor biology, molecular classification, and genetic testing.

The therapeutic landscape is rapidly evolving. HIF-2α inhibition has established proof of principle for genotype-directed treatment in von Hippel- Lindau (VHL)-associated RCC. Emerging strategies include next-generation HIF inhibitors, immunotherapy-based combinations, metabolism-directed therapies for fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient RCC, and biomarker-driven approaches to improve risk stratification and treatment selection.

Despite these advances, important challenges remain, including refining risk-adapted surveillance, optimizing intervention thresholds, developing syndrome-specific systemic therapies, and generating stronger prospective evidence.  The authors underscore that the future of hereditary kidney cancer care lies in integrating pathology, germline genetics, surveillance, surgery, and pathway-directed systemic therapy to deliver truly individualized precision medicine.

Read the full article: https://pubmed.ncbi.nlm.nih.gov/42580957/